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Summary
Background.— Open-heart surgery can result in adhesions, which can complicate resternotomy.Paediatric;
Cardiac reoperation;
Surgery;
Complications;
Aims.— To document the occurrence of adhesions after the use of a new collagen membrane;
to evaluate its tolerability; and to compare surgical parameters with control patients.
Methods.— Paediatric patients who underwent cardiac surgery with the collagen membrane
(CovaTM CARD; Biom’up, Saint Priest, France) were analysed retrospectively for levels of adhe-
sion and tolerability. The times of dissection and intervention and the transfusion of packed red
Abbreviations: CI, conﬁdence interval; ECC, extracorporeal circulation; ePTFE, expanded polytetraﬂuoroethylene; RBC, red blood cells;
SD, standard deviation.
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Collagen membrane
blood cells and haemostatic products were compared to a historic cohort who did not receive
an anti-adhesion device.
Results.— From January 2010 to December 2011, 36 patients received a collagen membrane.
Nineteen re-interventions were performed, after a mean of 169 days. No grade 3 adhesions were
observed and no tolerability problems were reported. During re-interventions after more than
30 days, the propensity score-adjusted durations of dissection and the total process for patients
with and without a collagen membrane were 32 vs 41minutes and 151 vs 182minutes, respec-
tively (not signiﬁcant). The mean quantities of red blood cells and biological glue administered
in the two groups were 98 vs 139mL and 1.2 vs 0.5mL, respectively (not signiﬁcant).
Conclusions.— This feasibility study shows the potential use of the new membrane in paediatric
patients, both in terms of prevention from severe adherence and tolerability. This is the ﬁrst
study of this membrane in humans. A prospective, controlled study is necessary to provide
strong evidence of its efﬁciency.
© 2013 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— La réalisation de chirurgies à cœur ouvert peut entraîner des adhérences qui
peuvent compliquer la re-sternotomie.
Objectif.— Évaluer la survenue d’adhérences après utilisation d’une membrane en collagène ;
évaluer sa tolérance dans une population pédiatrique ; et comparer des paramètres chirurgicaux
chez les témoins.
Méthodes.— Une étude rétrospective a été conduite chez des enfants ayant subi une chirurgie
cardiaque et ayant bénéﬁcié de la membrane de collagène (CovaTM CARD ; Biom’up, Saint Priest,
France). Les degrés d’adhérence à la réintervention chirurgicale et les données de tolérance
ont été colligés. Les durées de dissection chirurgicale et réintervention, l’utilisation de culots
globulaires rouges et d’agents hémostatiques ont été comparées à une série de patients n’ayant
pas bénéﬁcié d’anti-adhérent.
Résultats.— Entre janvier 2010 et décembre 2011, 36 patients ont été sélectionnés dans le
groupe membrane. Dix-neuf réinterventions ont été réalisées après un délai moyen de 169 jours.
Aucune adhésion de grade sévère n’a été observée ni de problème de tolérance. Pour les réin-
terventions après 30 jours, les durées de dissection et d’intervention ont été respectivement de
32 et 151minutes contre 41 et 182minutes dans le groupe témoin (non signiﬁcatif). Les quan-
tités moyennes de culots transfusés et de colles biologiques utilisées dans les groupes ont été
respectivement de 98 contre 139mL et de 1,2 contre 0,5mL (non signiﬁcatif).
Conclusions.— Cette étude de faisabilité montre l’intérêt potentiel de la nouvelle membrane
dans une population pédiatrique tant sur le plan de la prévention des adhérences sévères que de
la tolérance. C’est la première étude chez l’homme avec cette membrane. Une étude prospec-
tive contrôlée est nécessaire pour apporter la preuve de son éventuelle supériorité par rapport
aux stratégies habituelles.
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ackground
ardiac reoperations are increasingly common, espe-
ially among paediatric patients with cardiac disease.
pproximately 10% of cardiac operations involve repeat ster-
otomies [1]. There is a risk of re-entry injury due to the
resence of adhesions that can obscure the cardiac anatomy
2]. The surgical trauma to the pericardiac mesothelium dur-
ng open-heart surgery can result in a decrease in ﬁbrinolytic
ctivity and the formation of adhesions at the intervention
ites [3]. Therefore, re-interventions may be complicated
y the development of dense, ﬁbrous retrosternal or peri-
ardiac adhesions. As a consequence, re-sternotomies can
e dangerous and surgery is complicated because the
urgeon needs to use sharp instruments that might dam-
ge the tissues and cause potentially serious iatrogenic
aemorrhagic events [1,2,4—7]. Adverse events related to
T
gs droits réservés.
eoperation can lead to poor patient outcome and higher
ost [8].
These complications of reoperations have prompted
xperimental studies to prevent or decrease adhesion
ormation and thus decrease the risks associated with reope-
ation.
Here, we describe our clinical experience of the use of
new collagen membrane which aims to prevent surgical
dhesions.
ethodshis single-centre, retrospective cohort study evaluated a
roup of patients treated with a collagen membrane, and
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compared this group to a historic cohort of patients not
treated with a membrane.
Objectives
Our main objectives were to evaluate: (1) the occurrence
of adhesions during surgical re-interventions with collagen
membrane and (2) the tolerability and the morbidity related
to the presence of adhesions after the use of the collagen
membrane. Our secondary objectives were to evaluate and
compare the duration of dissection, the total duration of re-
intervention and the volumes of packed red blood cells (RBC)
and biological glue used during surgical re-interventions
among those treated with and without collagen membrane.
Evaluation criteria
As there is no speciﬁc classiﬁcation for the severity of adhe-
sions in cardiopaediatric surgery, adhesions among patients
in the collagen membrane group were graded according to
the levels of adhesion described by Lodge et al. [9] (Table 1).
No record of adhesion severity in the control arm was avail-
able, as we only started using this classiﬁcation scheme after
the introduction of the collagen membrane.
Adhesions among collagen membrane recipients were
also characterized by the risk zone of their occurrence, as
described in Table 1. Zone A is the ﬁrst zone encountered
during re-intervention. Resternotomy in a patient with adhe-
sions in zone A is accompanied by the risks of damaging the
heart or any other structure that can stick to the sternum.
This can be fatal, as the ECC has not yet been implemented,
and the patient may die from haemorrhagic shock, espe-
cially as access to a femoro—femoral ECC is impossible in
young children. Adhesions in zone B can affect the second
stage of surgery, which begins once the sternal retractor is
in place and the structures needed to start the ECC (aorta
Table 1 Description of the levels of adhesion and adhe-
sion risk zones.
Description
Level of adhesion
Grade 0 Absence of adhesion
Grade 1 Low adhesion (possibility to lyse it
with the ﬁnger)
Grade 2 Moderate adhesion (possibility to
lyse it with scissors)
Grade 3 High adhesion requiring the use of
an electrical bistoury in order to
perform the dissection
Adhesion risk zone
A Anatomic structures located in the
sternotomy zone
B Necessary mediastinum elements
for the installation of ECC
(ascending aorta, superior vena
cava, part of the right atrium)
ECC: extracorporeal circulation.
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nd right atrium) are dissected. This step is somewhat less
angerous because the wound can be more easily controlled
s the heart is better exposed. The morbidity related to
he presence of adhesions was assessed as any complica-
ion related to the presence of adhesions mentioned in the
edical charts, regardless of the severity.
The evaluation of adhesion grade was not blinded. Poten-
ial undesirable effects related to the collagen membrane,
uch as inﬂammatory or allergic reactions, were collected
n order to evaluate its tolerability.
As adhesions were not recorded in the control arm, the
ollowing objective parameters were retrieved for com-
arison between the groups. The duration of dissection of
he re-intervention was the time between the ﬁrst surgi-
al incision and the start of ECC. The volume of RBC was
ssessed, taking into account all administration of RBC dur-
ng the procedure. The volume of biological glue used during
e-intervention was the total amount of Tissucol® (Baxter,
eerﬁeld, USA).
tudy membrane and procedure
he study membrane is a resorbable, malleable porcine col-
agen membrane called CovaTM CARD (Biom’up, Saint Priest,
rance) (Fig. 1), which acts as a barrier between the heart
nd the surrounding tissues. It also promotes tissue regen-
ration [10,11]. It is a class III device that obtained a CE
pproval in 2009. The membrane is available in two sizes
30× 40mm and 40× 60mm), according to the weight of
he child. The membrane has to be moisturized for a few
inutes in a physiological serum to make it more ﬂexible.
t can be cut as necessary, in order to be able to place it
n delicate structures; and can be ﬁxed with sutures. It is
pplied next to the right atrium, the aorta and the sternum,
efore the sternal closure.
election criteria for the collagen membrane
roup
atients in the collagen membrane group were those who
ad received the collagen membrane during January 2010 to
ecember 2011 during surgery for a congenital cardiopathy
equiring repeat scheduled open-heart surgery with a ﬁrst
e-intervention scheduled less than 24months after the ﬁrst
ntervention with median sternotomy and requiring ECC.
election criteria for the control population
ontrol patients were those who had an initial interven-
ion using an approach with median sternotomy during 2009;
ad a re-intervention performed by the same cardiac sur-
eon as the re-interventions performed in the membrane
roup; had a re-intervention occurring more than 30 days
fter the original procedure that was performed using an
pproach with median sternotomy and requiring ECC. In all
ontrol patients, the pericardium was not closed after the
rst procedure.ata collection and analysis
aseline parameters are presented as means and standard
eviations (SDs) for quantitative variables and numbers
436 X. Armoiry et al.
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Figure 2. Adhesion levels observed in the membrane cohort
according to the delay of re-intervention in (A) risk zone A (ster-
notomy zone) and (B) risk zone B (ECC zone). ECC: extracorporealigure 1. CovaTM CARD before implantation.
percentages) for qualitative variables. To adjust for
aseline characteristics between the two groups, we esti-
ated propensity scores using a logistic regression model
gender, age at initial surgery, delay of re-intervention, age
t re-intervention and weight at revision surgery). We then
ompared re-intervention parameters using linear models
ith a covariate adjustment on these propensity scores.
djusted means with 95% conﬁdence intervals (CIs) are pre-
ented.
esults
se of the collagen membrane
rom January 2010 to December 2011, 36 children (25 boys;
1 girls) with congenital cardiopathy received a collagen
embrane after a ﬁrst cardiac surgery and were included in
his study. Among them, two received a second membrane
fter a second surgery and one patient received a total of
our membranes after four surgeries performed during the
bservation period. In total, 41 collagen membranes were
mplanted during 41 surgeries. The mean age of the patients
t the time of the ﬁrst intervention was 13.8± 33.7months
range: 0.1—200months).
Nineteen re-interventions were undertaken during the
bservation period on a total of 14 patients, of whom two
ad two re-interventions and one had four re-interventions.
o re-intervention was due to an undesirable event related
o the initially implanted anti-adhesion membrane. Re-
nterventions occurred within a mean delay after initial
urgery of 169± 166 days (range: 3—558 days). Twelve re-
nterventions (63%) occurred after a delay of more than
0 days.
The adhesion levels for the 19 re-interventions performed
fter the installation of the collagen membranes are shown
n Fig. 2. In risk zone A (sternotomy zone), regardless of the
e-intervention delay, no grade 2/3 adhesion was observed
nd 89% of patients had no adhesion (Fig. 2A). Beyond a
e-intervention delay of 30 days, 17% of patients had grade
adhesions. In risk zone B (ECC zone), there were some
rade 1/2 adhesions, but no severe adhesions (grade 3)
Fig. 2B). Beyond a re-intervention delay of 30 days, the
circulation.
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Table 2 Demographic characteristics in the two populations.
Membrane group
(n = 12)
Historical control group
(n = 13)
Gender
Male 9 (75.0) 6 (46.2)
Female 3 (25.0) 7 (53.8)
Age at initial surgery (months) 4.1± 5.5 4.0± 7.2
Age at re-intervention (months) 12.7± 5.0 13.0± 7.9
Delay of re-intervention (months) 8.6± 4.7 8.9± 5.6
Weight at revision surgery (kg) 8.5± 1.6 8.1± 2.9
Data are expressed as number (%) or mean± standard deviation.
Table 3 Cardiopathy and previous and re-surgery of the compared populations.
Congenital cardiopathy Previous surgery Re-surgery Membrane group
(n = 12)
Historical control group
(n = 13)
Fallot SPS Correction 1 3
PAIVS SPS CBP 3 0
PAVSD SPS Rastelli 1 0
Tricuspid atresia SPS CBP 2 0
VSD PB Correction 1 6
Single ventricle PB CBP 1 1
Single ventricle PB Fontan 0 1
MR Mitral Repair MVR 2 1
Cardiomyopathy VAD Transplantation 1 1
CBP: cavo-bipulmonary; MR: mitral regurgitation; MVR: mitral valve replacement; PAIVS: pulmonary atresia with intact interventricular
septum; PAVSD: pulmonary atresia with ventricular septum defect; PB: pulmonary banding; SPS: systemic-pulmonary shunt; VAD:
ventricular assistance device; VSD: ventricular septal defect.
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(rates of grade 1 and grade 2 adhesions were 42% and 25%,
respectively. Tolerability of the membrane was good as no
serious or minor undesirable effects were observed, in terms
of infection, allergy, intolerance, inﬂammatory signs or sec-
ondary vascular rupture. There were no complications due
to the presence of adhesions during the re-interventions
performed in the membrane group; and no haemorrhagic
accidents were recorded.
Comparison with historical controls
Thirteen patients met the selection criteria for the control
population; none of these patients beneﬁted from a speciﬁc
preventative measure of surgical adhesions. Demographic
characteristics for these patients are shown in Table 2, along
with data for the 12 patients from the membrane group
who underwent re-intervention after a delay of more than
30 days. Although the number of patients in each group is
limited, patient characteristics were similar. However, the
aetiologies were heterogeneous (Table 3). The occurrence of
surgical adhesions was not related to the underlying cardiac
pathology, but only related to the injury of tissues resulting
from the surgical approach due to a resternotomy.
The durations of the dissection and the total re-
intervention were not signiﬁcantly different between the
groups (Table 4). RBC and biological glue use were also not
M
h
oigniﬁcantly different between the groups, but numerically
ore RBC was used in the control group (Table 4). In both
roups, no aorta scars or haemorrhagic events related to
dhesions were reported. In the membrane group, durations
f dissection were not related to the degree of adhesions
Table 5).
iscussion
n this exploratory study, which evaluated and compared the
ovaTM CARD cohort to a historic cohort of patients who did
ot beneﬁt from any techniques of adhesion, there were no
rade 3 adhesions in the membrane group. The good toler-
bility of this membrane, which has a European Economic
ommunity grading, was also conﬁrmed.
Strategies for reducing re-entry injury vary greatly
etween centres and operators, with therapeutic options
arying between no prevention measures to partial
losure of the pericardium or the installation of an
nti-adhesion device or expanded polytetraﬂuoroethylene
ePTFE) [12,13].The use of Sepraﬁlm® membrane (Genzyme, Cambridge,
ass, USA), composed of carboxymethyl cellulose and
yaluronic acid, has been shown to reduce the grade
f adhesions and the duration of dissection in patients
438 X. Armoiry et al.
Table 4 Comparison of re-intervention parameters between the two populations.
Membrane group
(n = 12)
Historical control group
(n = 13)
Pa
Duration of dissectionb (minutes) 32 (24—40) 41 (33—48) 0.16
Total duration of re-interventionc (minutes) 151 (120—183) 182 (146—218) 0.23
Volume of RBC transfused at revision surgeryb (mL) 98 (20—177) 139 (65—213) 0.48
Volume of biological glue used at the revision surgeryd (mL) 1.2 (0.2—2.2) 0.5 (0—1.5) 0.34
Data are expressed as adjusted mean (95% conﬁdence interval).
a P-values were obtained using linear regression analysis, adjusted for propensity scores (estimated from logistic regression with baseline
characteristics; C score = 0.821).
b Data are missing for one patient in each group.
c Data are missing for two patients in the membrane group and ﬁve patients in the control group.
d Data are missing for one patient in the control group.
Table 5 Time of dissection according to the level of
adhesion in the membrane group.
Level of adhesion Duration of dissection
(minutes)
Zone A: 0; zone B: 0 (n = 4) 33± 9
Zone A: 0; zone B: 1 (n = 4) 37± 16
Zone A: 0; zone B: 2 (n = 1) 28
Zone A: 1; zone B: 2 (n = 2) 32± 1
Data are expressed as mean± standard deviation.
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expected to increase the time for the dissection of tissuesndergoing surgery for congenital cardiopathy [14]. More
ecently, the Repel CV® membrane (SyntheMed, Iselin, USA),
ade from polylactic acid, has been shown to reduce
he occurrence of severe adhesions compared to a con-
rol group, and the bioresorbable device appeared to be
afe [9]. However, there are two main disadvantages of
hese membranes, namely their composition and their lack
f mechanical resistance. Despite its efﬁcacy in preventing
ericardial adhesions, the Repel CV® device has been associ-
ted with inﬂammatory reactions due to polylactic acid [15].
epraﬁlm®’s biological composition does not allow it to be
pplied onto wet sutures, which is a common situation in
ardiac surgery. Also, sutures can easily be displaced or bro-
en by heart beats [16]. Furthermore, the resorption of its
ain component does not involve naturally present endoge-
ous enzymes (like collagenases), but occurs by hydrolysis,
hich causes the release of non-metabolized fragments into
he mediastinal cavity [15].
In this context, no recommendation has yet been estab-
ished to guide the clinician in choosing a technique to
revent adhesions. As soon as it was commercialized, the
ovaTM CARD device raised signiﬁcant interest among paedi-
tric cardiac surgeons, due to its ease of use and handling.
he CovaTM CARD membrane was ﬁrst evaluated for car-
iac surgery through a pre-clinical model conducted on 16
heep, which underwent sternotomy followed by scariﬁca-
ion of the heart [10]. Three approaches were compared:
ericardium left open or installation of a hyaluronic acid
nd carboxymethylcellulose or CovaTM CARD before closure.
xplanted hearts were evaluated for inﬂammatory response
b
a
end ﬁbrosis. The CovaTM CARD membrane was nearly com-
letely absorbed within 4months and was replaced by
oosely adherent tissue. No inﬂammatory reaction was seen,
nd ﬁbrosis was minimal. A composite score (tightness of
dhesions, inﬂammation and ﬁbrosis) was signiﬁcantly lower
n the CovaTM CARD than in the Sepraﬁlm® group [10]. A
econd study involved 18 sheep that underwent sternotomy
nd an ECC of 30minutes [11]. Three options were tested:
ericardium left open or use of an ePTFE or CovaTM CARD
embrane. Four months after surgery, the best adhesion
core was obtained in the CovaTM CARD group. However,
he presence of the collagen membrane allowed the re-
pithelialization of the heart [11]. Despite its CE approval,
o clinical studies on the CovaTM CARD membrane had been
ublished when it was commercialized. Therefore, we eval-
ated its potential impact in paediatric cardiac surgery.
ur study is the ﬁrst reported experience on CovaTM CARD
embrane in congenital cardiopathy surgeries. Our results
onﬁrm its potential beneﬁt in preventing severe adhe-
ions as no grade 3 adhesions were reported, regardless
f the delay of re-intervention after initial surgery and
he risk zone. The absence of severe adhesion in the ster-
otomy zone is particularly satisfactory considering that,
s stated by the French National Authority for Health, the
omplications related to re-opening the sternum in the pres-
nce of adhesions between the sternum and the heart can
e life-threatening [17].
No signiﬁcant differences were found for the duration of
issection or the total duration of surgery between the mem-
rane and control groups. Also, there was no link between
issection time and level of adhesions in the membrane
roup. However, these results should be interpreted with
aution due to the low number of patients evaluated. In a
andomized study by Lodge et al. [9], which reported signif-
cantly less severe adhesions with the Repel CV® membrane
ompared with no barrier, there was no difference in the
uration of dissection between the groups, although there
as a small, but signiﬁcant increase in the duration of dis-
ection with severe versus no severe adhesions. Intuitively,
he presence of adhesions that complicate surgery would beefore the installation of ECC. However, if there are strong
dhesions, the surgeon may choose to clear the necessary
lements quickly, then start ECC, and ﬁnish the dissection
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under ECC, which therefore does not increase the time of
dissection, which was deﬁned as the time from ﬁrst incision
to start of ECC. A better parameter may be the complete
time of intervention, but only if the same types of inter-
ventions by the same surgeon are compared, which would
require a much higher number of patients.
There were no signiﬁcant differences between the groups
in terms of consumption of medical resources (RBC and
biological glue), which is consistent with the absence of
any haemorrhagic wounds or other preoperation undesired
events in the two groups. However, these criteria are poten-
tially useful for future studies, considering the risk of
haemorrhagic complications associated with the presence
of adhesions.
It should be noted that only considering such criteria may
be restrictive. In fact, the presence of major adhesions may
sometimes compel the surgeon to use other approaches [18].
The major limitations of this study were the non-
randomization of patients, the low number of patients, the
monocentric aspect of the study and the use of historical
controls. However, the results of this study are promising,
and we are currently planning to test this membrane further
in a prospective, randomized, controlled study.
Conclusions
The CovaTM CARD membrane was used with good tolerabil-
ity in this ﬁrst human clinical study including 36 paediatric
patients. A high level of proof study on a higher number of
patients is to be carried out in order to further evaluate its
efﬁciency in the prevention of adhesions.
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